When did ResMed report Q4 2025 earnings?

ResMed (RMD) reported Q4 2025 earnings on July 31, 2025 after market close.

What were ResMed's Q4 2025 revenue and EPS?

ResMed reported revenue of $1.3B and diluted EPS of $2.55 for Q4 2025.

Did ResMed beat estimates in Q4 2025?

Revenue beat the consensus estimate of $1.3B by -. EPS beat the consensus estimate of $2.55 by $0.00.

How did ResMed's Q4 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 10.2% from $1.2B a year earlier and diluted EPS grew 22.6% from $2.08.

Where can I find ResMed's Q4 2025 SEC filings?

You can read the 10-K periodic report (0000943819-25-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.

ResMed RMD Q4 2025 Annual earnings

Reported July 31, 2025 · After market close

Revenue$1.3BIn line Diluted EPS$2.55In line

Revenue estimate$1.3B

EPS estimate$2.55

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$1.5B

EPS estimate$2.90

Financials

Q4 2025

Income statement

See full

Revenue$1.3B+10.2%

Gross profit$820.1M+14.6%

Operating income$454.5M+19.2%

Net income$379.7M+29.9%

EPS (diluted)$2.58+30.3%

Balance sheet

See full

Cash & equivalents$1.2B+407%

Total debt$861.7M-2.5%

Total equity$6.0B+22.7%

Total assets$8.2B+18.9%

Cash flow

See full

Operating cash flow$538.8M+22.4%

CapEx$30.6M+22.9%

Free cash flow$508.2M+22.4%

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$37.52B+33.4%

Enterprise value$37.18B+29.2%

P/E26.8×-0.8×

P/S7.3×+1.3×

Profitability

See full

Gross margin59.4%+2.7pp

Operating margin32.7%+4.6pp

Net margin27.2%+5.4pp

FCF margin32.3%+4.5pp

Returns & leverage

See full

Return on equity25.9%+3.2pp

Debt / equity0.1×0.0×

Current ratio3.4×+0.9×

Segments

By segment

See full

Sleep and Breathing Health$1.2B—

Residential Care Software$167.0M—

By product

See full

Sleep And Breathing Health$1.2B—

Residential Care Software$167.0M—

Versus estimates

Revenue

Q3 2026$1.4BBeat by $11.5M Q2 2026$1.4BBeat by $22.3M Q1 2026$1.3BBeat by $2.3M

Q4 2025$1.3BIn line

Q3 2025$1.3BBeat by $3.6M Q2 2025$1.3BBeat by $15.4M

Diluted EPS

Q3 2026$2.86Beat by $0.07 Q2 2026$2.81Beat by $0.07 Q1 2026$2.55Beat by $0.04

Q4 2025$2.55In line

Q3 2025$2.37Miss by $0.01 Q2 2025$2.43Beat by $0.11

Ask the moment ResMed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ResMed report Q4 2025 earnings?: ResMed (RMD) reported Q4 2025 earnings on July 31, 2025 after market close.
What were ResMed's Q4 2025 revenue and EPS?: ResMed reported revenue of $1.3B and diluted EPS of $2.55 for Q4 2025.
Did ResMed beat estimates in Q4 2025?: Revenue beat the consensus estimate of $1.3B by -. EPS beat the consensus estimate of $2.55 by $0.00.
How did ResMed's Q4 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 10.2% from $1.2B a year earlier and diluted EPS grew 22.6% from $2.08.
Where can I find ResMed's Q4 2025 SEC filings?: You can read the 10-K periodic report (0000943819-25-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.